SCHEMBL1422341

SCHEMBL1422341

COC(=O)CCc1ccc(NS(C)(=O)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
HPGD P15428 2/20 0.56
ALDH1A1 P00352 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
IDO1 P14902 1/20 0.54
GRIN1 Q05586 8/20 0.51
GRIN2B Q13224 8/20 0.51
KCNH2 Q12809 2/20 0.50
RECQL P46063 1/20 0.49
F2 P00734 1/20 0.48
F10 P00742 1/20 0.48
PRSS1 P07477 1/20 0.48
CACNA1F O60840 1/20 0.48
CHRM2 P08172 1/20 0.48
ACHE P22303 1/20 0.48
AGTR1 P30556 1/20 0.48
DRD3 P35462 1/20 0.48
CACNA1D Q01668 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8864614 0.86 CYP4F2 (0.60) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL6714485 0.84 ALDH1A1 (0.53) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL23647680 0.83 SMN1; SMN2 (0.59) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL657740 0.83 ALDH1A1 (0.64) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL10750177 0.83 ALDH1A1 (0.59) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL22922181 0.82 CYP4F2 (0.59) ALDH1A1LMNAHTTIDO1EPHX2
SCHEMBL9440112 0.82 KDM4E (0.58) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL9625062 0.82 HPGD (0.57) KDM4EHPGDALDH1A1LMNAHTT
SCHEMBL14717782 0.81 EPHX2 (0.56) HPGDALDH1A1LMNAHTTIDO1
SCHEMBL5737290 0.81 ALDH1A1 (0.56) KDM4EHPGDALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170334-B1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION UNIV EMORY (US) 2021-03-17 EP disclosed
US-9265768-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-02-23 US disclosed
US-9079852-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2015-07-14 US disclosed
EP-2760838-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2014-08-06 EP disclosed
US-20140142074-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-05-22 US disclosed
US-20140142074-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-05-22 US disclosed
US-20140142074-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2014-05-22 US disclosed
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection LIOTTA DENNIS C (US) 2014-01-30 US disclosed
CN-103497114-A NMDA receptor antagonists for neuroprotection UNIV EMORY 2014-01-08 CN disclosed
CN-103058957-A NMDA receptor antagonists for neuroprotection UNIV EMORY 2013-04-24 CN disclosed
US-20130079313-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-03-28 US disclosed
CN-101815518-B NMDA receptor antagonists for neuroprotection UNIV EMORY 2013-01-09 CN disclosed
CN-102762207-A NMDA receptor antagonists for the treatment of neuropsychiatric disorders UNIV EMORY 2012-10-31 CN disclosed
US-20110160223-A1 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders EMORY UNIVERSITY 2011-06-30 US disclosed
EP-2296658-A2 NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS Emory University (US) 2011-03-23 EP disclosed
CN-101815518-A nmda receptor antagonists for neuroprotection UNIV EMORY 2010-08-25 CN disclosed
EP-2170334-A1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION Emory University (US) 2010-04-07 EP disclosed
WO-2009137843-A2 NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS EMORY UNIVERSITY (US) 2009-11-12 WO disclosed
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection EMORY UNIVERSITY 2009-10-08 US disclosed
WO-2009006437-A1 NMDA RECEPTOR ANTAGONISTS FOR NEUROPROTECTION EMORY UNIVERSITY (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079313-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE3A KDM4E 373/4885HPGD 145/4885ALDH1A1 59/4885
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 KDM4E 2576/4885HPGD 3637/4885ALDH1A1 2664/4885
US-20110160223-A1 NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders GRIN2A, GRIN2B, GRIN1 KDM4E 2156/4885HPGD 816/4885ALDH1A1 2039/4885
US-20140031363-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 KDM4E 2527/4885HPGD 3532/4885ALDH1A1 2668/4885
US-20140142074-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE4B, PDE3A KDM4E 373/4885HPGD 145/4885ALDH1A1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.